Bauxite fibrosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Template)
 
(6 intermediate revisions by 2 users not shown)
Line 15: Line 15:
{{CMG}}
{{CMG}}


{{Editor Help}}
{{SK}} Shaver's disease; corundum smelter's lung; bauxite lung; bauxite smelters' disease


'''Bauxite pneumoconiosis''', also known as ''Shaver's disease'', ''corundum smelter's lung'', ''bauxite lung'' or ''bauxite smelters' disease'', is a progressive form of [[pneumoconiosis]] caused by exposure to bauxite fumes which contain [[aluminium]] and silica particulates. Initially, the disease appears as [[alveolitis]], and then progresses to [[emphysema]]. Patients may develop [[pneumothorax]] (collapsed lung).
==Overview==
Bauxite pneumoconiosis is a progressive form of [[pneumoconiosis]] caused by exposure to bauxite fumes which contain [[aluminium]] and silica particulates.


==Historical Perspective==
*[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
*In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
*In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
==Classification==
*[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
:*[group1]
:*[group2]
:*[group3]
*Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
==Pathophysiology==
*The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
*On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
==Causes==
* [Disease name] may be caused by either [cause1], [cause2], or [cause3].
* [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
* There are no established causes for [disease name].
==Differentiating [disease name] from other Diseases==
*[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
:*[Differential dx1]
:*[Differential dx2]
:*[Differential dx3]
==Epidemiology and Demographics==
It is typically seen in workers involved in the smelting of bauxite to produce corundum.
It is typically seen in workers involved in the smelting of bauxite to produce corundum.


==Natural History, Complications and Prognosis==
===Natural History===
Initially, the disease appears as [[alveolitis]], and then progresses to [[emphysema]].


===Complications===
Patients may develop [[pneumothorax]] ([[collapsed lung]]).
===Prognosis===
== Diagnosis ==
===Diagnostic Criteria===
*The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
:*[criterion 1]
:*[criterion 2]
:*[criterion 3]
:*[criterion 4]
=== Symptoms ===
*[Disease name] is usually asymptomatic.
*Symptoms of [disease name] may include the following:
:*[symptom 1]
:*[symptom 2]
:*[symptom 3]
:*[symptom 4]
:*[symptom 5]
:*[symptom 6]
=== Physical Examination ===
*Patients with [disease name] usually appear [general appearance].
*Physical examination may be remarkable for:
:*[finding 1]
:*[finding 2]
:*[finding 3]
:*[finding 4]
:*[finding 5]
:*[finding 6]
=== Laboratory Findings ===
*There are no specific laboratory findings associated with [disease name].
*A  [positive/negative] [test name] is diagnostic of [disease name].
*An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
*Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
===Imaging Findings===
*There are no [imaging study] findings associated with [disease name].
*[Imaging study 1] is the imaging modality of choice for [disease name].
*On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
*[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
=== Other Diagnostic Studies ===
*[Disease name] may also be diagnosed using [diagnostic study name].
*Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
== Treatment ==
=== Medical Therapy ===
*There is no treatment for [disease name]; the mainstay of therapy is supportive care.
*The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
*[Medical therapy 1] acts by [mechanism of action 1].
*Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
=== Surgery ===
*Surgery is the mainstay of therapy for [disease name].
*[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
*[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
=== Prevention ===
*There are no primary preventive measures available for [disease name].
*Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
*Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test].
==References==
{{Reflist|2}}
[[Category:Pulmonology]]


{{Respiratory pathology}}
{{Respiratory pathology}}
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 16:05, 7 June 2016

Template:DiseaseDisorder infobox

WikiDoc Resources for Bauxite fibrosis

Articles

Most recent articles on Bauxite fibrosis

Most cited articles on Bauxite fibrosis

Review articles on Bauxite fibrosis

Articles on Bauxite fibrosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bauxite fibrosis

Images of Bauxite fibrosis

Photos of Bauxite fibrosis

Podcasts & MP3s on Bauxite fibrosis

Videos on Bauxite fibrosis

Evidence Based Medicine

Cochrane Collaboration on Bauxite fibrosis

Bandolier on Bauxite fibrosis

TRIP on Bauxite fibrosis

Clinical Trials

Ongoing Trials on Bauxite fibrosis at Clinical Trials.gov

Trial results on Bauxite fibrosis

Clinical Trials on Bauxite fibrosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bauxite fibrosis

NICE Guidance on Bauxite fibrosis

NHS PRODIGY Guidance

FDA on Bauxite fibrosis

CDC on Bauxite fibrosis

Books

Books on Bauxite fibrosis

News

Bauxite fibrosis in the news

Be alerted to news on Bauxite fibrosis

News trends on Bauxite fibrosis

Commentary

Blogs on Bauxite fibrosis

Definitions

Definitions of Bauxite fibrosis

Patient Resources / Community

Patient resources on Bauxite fibrosis

Discussion groups on Bauxite fibrosis

Patient Handouts on Bauxite fibrosis

Directions to Hospitals Treating Bauxite fibrosis

Risk calculators and risk factors for Bauxite fibrosis

Healthcare Provider Resources

Symptoms of Bauxite fibrosis

Causes & Risk Factors for Bauxite fibrosis

Diagnostic studies for Bauxite fibrosis

Treatment of Bauxite fibrosis

Continuing Medical Education (CME)

CME Programs on Bauxite fibrosis

International

Bauxite fibrosis en Espanol

Bauxite fibrosis en Francais

Business

Bauxite fibrosis in the Marketplace

Patents on Bauxite fibrosis

Experimental / Informatics

List of terms related to Bauxite fibrosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Shaver's disease; corundum smelter's lung; bauxite lung; bauxite smelters' disease

Overview

Bauxite pneumoconiosis is a progressive form of pneumoconiosis caused by exposure to bauxite fumes which contain aluminium and silica particulates.

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

  • [Disease name] may be caused by either [cause1], [cause2], or [cause3].
  • [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
  • There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

It is typically seen in workers involved in the smelting of bauxite to produce corundum.

Natural History, Complications and Prognosis

Natural History

Initially, the disease appears as alveolitis, and then progresses to emphysema.

Complications

Patients may develop pneumothorax (collapsed lung).

Prognosis

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test].

References

Template:Respiratory pathology

Template:WikiDoc Sources